The MM Journey Continues: CD38-targeting Agents in the Relapsed/Refractory Setting

Please Log In or Register to continue.

Release Date: March 27, 2024
Expiration Date: March 27, 2025

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity focuses on the efficacy and safety of therapies that target CD38 for patients with relapsed or refractory multiple myeloma (RRMM). The distinguished faculty panel will engage in a detailed analysis of how currently approved, emerging and combination CD38-targeting therapies may be used in patients with RRMM. Through a discussion of clinical trials of CD38-targeting agents with the potential to impact clinical practice in RRMM and factors that are important for optimizing treatment in patients who have failed one or more lines of therapy, faculty will provide guidance and recommendations for improving outcomes in this challenging patient population.

Target Audience

The target audience is the multidisciplinary team of community-based hematology/oncology physicians; academic and community-based oncology physicians; community-based advanced practice providers (NPs/PAs) in hematology/oncology; and others in the multidisciplinary treatment team for patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Compare and contrast treatment considerations in the MM patient who has failed one line of therapy versus patients who have failed two lines versus multi-refractory patients
  • Summarize safety and efficacy data of ongoing clinical trials investigating anti-CD38 mAbs in the relapsed/refractory MM treatment setting


The MM Journey Continues: CD38-targeting Agents in the Relapsed/Refractory Setting

  • How is CD38 currently being targeted in the relapsed/refractory multiple myeloma (RRMM) setting?
  • What clinical trials are currently investigating new combinations of CD38-targeting agents and what impact could they have on clinical practice?
  • What disease- and patient-specific factors should clinicians consider when developing therapeutic strategies for RRMM patients?

Instructions for Participation and Credit

This activity is eligible for credit through March 27, 2025. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CE credit may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Joshua Richter, MD, FACP
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family Chelsea Medical Center at Mount Sinai
New York City, New York

Dr. Joshua Richter received his medical degree from New York Medical College. He completed an internal medicine residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter served as Clinical Assistant Professor at Rutgers University, New Brunswick, New Jersey, and worked in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. He is currently an Associate Professor of Medicine at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai and Director of Myeloma at Blavatnik Family Chelsea Medical Center at Mount Sinai in New York City.

Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, and the British Journal of Haematology. Dr. Richter specializes in multiple myeloma as well as other plasma cell dyscrasias such as amyloidosis and Waldenstrom’s macroglobulinemia. His clinical research interests focus on multi-functional antibodies and precision medicine. 

Andrew Yee, MD
Clinical Director, Center for Multiple Myeloma
Massachusetts General Cancer Center
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Andrew Yee received his medical degree from Harvard Medical School, followed by training in internal medicine at Massachusetts General Hospital and hematology and oncology at Dana-Farber Cancer Institute/Partners Cancer Care. He is currently the Clinical Director of the Center for Multiple Myeloma at Massachusetts General Cancer Center and Assistant Professor of Medicine at Harvard Medical School. 

Dr. Yee sees patients with multiple myeloma and plasma cell dyscrasias.  He is actively involved in clinical trials in multiple myeloma, where he leads several investigator-initiated trials and serves as principal investigator on a range of multicenter trials.   


MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Joshua Richter has relevant financial relationships to disclose related to speakers’ bureaus from Adaptive Biotechnologies, Bristol Myers Squibb Company, Janssen Pharmaceuticals, Inc., and Sanofi; and for consulting and advisory activities from AbbVie Inc., Bristol Myers Squibb, Genentech, Inc., Janssen, Karyopharm Therapeutics, Pfizer Inc., Sanofi, and Takeda Oncology.

Dr. Andrew Yee has relevant financial relationships to disclose related to consulting activities from AbbVie Inc., Adaptive Biotechnologies, Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GSK, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Oncopeptides AB, Prothena, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda Oncology. He has received research grants from Amgen, Bristol Myers Squibb, and Janssen.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices. ­­­

Planning Committee

Joan Meyer, RN, MHA, Executive Director; Sheri Sturgis, Strategy and Education Manager; Lillian McVey, Content Director; and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from sanofi-aventis US LLC.

©2024 MediCom Worldwide, Inc., 4607 Library Rd., Ste 220 #2001 · Bethel Park, PA, 15102, 267-716-5451
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.